Current Role:
Dr McFarlane has overall responsibility for the development and analytical validation of molecular diagnostic tests, from RUO and IUO Clinical Trial Assays through to IVD Companion Diagnostic (CDx) tests. She has worked for over 13 years in the field of translational molecular oncology
Previous Experience:
Prior to joining Almac, Dr McFarlane obtained a PhD from Queen’s University Belfast. She subsequently completed postdoctoral fellowships where she specialized in the identification and validation of novel therapeutic targets in the Ubiquitin Proteasome system.
Joined Almac:
2015
